Levact 2 clinical trials

A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation

This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.